THUMPD3-AS1 Is Correlated with Gastric Cancer and Regulates Cell Function through miR-1252-3p and CXCL17

Background: The problem facing gastric cancer treatment is the uncontrollable prognosis. LncRNAs are the current hotspot for gastric cancer prognostic markers. This study was targeted at determining THUMPD3-AS1 expression in gastric cancer, and then exploring whether THUMPD3-AS1 is associated with prognosis and its role in cancerous cell function. Methods: THUMPD3-AS1 expression levels were quantified in human tissues and cell lines. The prognostic biomarker potential of THUMPD3-AS1 was evaluated by Kaplan-Meier and multivariate Cox regression analyses. The biological impact of THUMPD3-AS1 in gastric cancer cells was investigated by WST-1, Transwell, and ROS accumulation assay. The binding between THUMPD3-AS1, miR-1252-3p and CXCL17 was verified by Luciferase reporter assay and RNA pulled down assay. Results: THUMPD3-AS1 was significantly decreased in gastric cancer tissues and cells by comparing them with normal ones. THUMPD3-AS1 was related to the advanced TNM stage, lymphatic infiltration and vascular infiltration. Downregulated THUMPD3-AS1 was associated with reduced 5‐year overall survival. Overexpression of THUMPD3-AS1 inhibits proliferation, migration, invasion and ROS accumulation of gastric cancer cells by regulation of miR-1252-3p and CXCL17. Conclusion: THUMPD3-AS1 could be a potent prognostic symbol for patients with gastric cancer. THUMPD3-AS1 provides a therapeutic potential for gastric cancer.